Small Molecule Therapeutics Design: Transforming Drug Discovery Through Ai-Driven Active Learning

On average, it takes 12-14 years and $2.6B dollars to develop and launch a new drug. The first step to this is the drug discovery phase. It typically takes around four years and in the case of small molecule therapeutics, requires over 4,000 compounds to be synthesized and screened. To significantly accelerate the innovation cycle, advance drug candidates to the clinical phase more rapidly and increase competitiveness, organizations require a transformational approach in drug discovery.

Drug Discovery transformation requires an integrated drug discovery workflow that combines both in silico and experimental approaches (or the ‘Virtual’ and the ‘Real’ (‘V+R’)). BIOVIA has created a dedicated, integrated solution for Small Molecule Therapeutics Design that includes all capabilities for V and R relevant to a modern discovery organization. It includes capabilities to design and perform physical lab experiments, to record results obtained and to register the molecules in a seamless and efficient way.

Learn more about this integrated, robust and agile solution for small molecule therapeutics design that combines virtual and real activities in a collaborative cloud environment.